表紙
市場調查報告書
商品編碼
1040463

免疫療法的全球市場(2021年∼2027年)

Immunotherapy Market 2021-2027

出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球免疫療法的市場規模,在預測期間內預計以13.8%大幅度的年複合成長率成長。帶動這個市場的主要原因,是在成人之間自體免疫疾病的盛行率高漲,及癌症的研究、資金籌措的投資持續增加等。再加上癌症治療的免疫療法獲承認,單株抗體身體的生產量增加,也促進市場成長。

還有在免疫療法市場上最近關注的非侵入性特定細胞可見化的技術,及人工智慧應用在病理學的技術等的技術開發,也是對市場成長有大幅貢獻的主要原因。可是,治療費高和消費者的購買力低,預計妨礙這個市場成長。

本報告提供全球免疫療法市場調查,市場概要,市場的推動因素與阻礙因素分析,COVID-19的影響,市場機會,各類型、用途、終端用戶、地區的市場分析,主要企業的簡介等系統性資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

  • 調查範圍
  • 分析師的洞察和目前市場趨勢

第3章 競爭情形

  • 主要企業分析
  • 主要策略分析

第4章 市場決策要素

  • 促進因素
  • 阻礙因素
  • 市場機會

第5章 市場細分化

  • 免疫療法的全球市場:各類型
    • 單株抗體
    • 癌症疫苗
    • 自體免疫查核點抑制劑
    • 白細胞介素和干擾素(細胞分裂素)
    • 其他
  • 免疫療法的全球市場:各用途
    • 癌症
    • 自體免疫及發炎性疾病
    • 感染疾病
    • 其他
  • 免疫療法的全球市場:各終端用戶
    • 醫院
    • 診斷中心
    • 其他

第6章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 其他地區

第7章 企業簡介

  • Advaxis, Inc.
  • AbbVie Inc.
  • AstraZeneca PLC
  • Adaptimmune Therapeutics plc.
  • Agenus, Inc.
  • Atara Biotherapeutics, Inc.
  • BellicumPhamaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • bluebird bio, Inc.
  • Chinook Therapeutics, Inc.
  • Celldex Therapeutics, Inc.
  • CytomX Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Incyte Corp.
  • Johnson & Johnson Services, Inc.
  • Jounce Therapeutics, Inc.
  • MacroGenics, Inc.
  • Novartis AG
  • Merck & Co., Inc.,
  • Xencor, Inc.
  • Ziopharm Oncology, Inc.
目錄
Product Code: OMR2024014

Global immunotherapy Market Size, Share &Trends Analysis Report by Type (Monoclonal Antibodies, Cancer Vaccines, Autoimmune Checkpoint Inhibitors, Interleukins and Interferons (Cytokinins), and Other Type), By Application (Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases, and Other Application), By End-User (Hospitals, Diagnostic Centers, and Other End-User) Forecast, 2021-2027

The global Immunotherapy market is projected to grow at a significant CAGR of 13.8% during the forecast period (2021-2027). The major factors that are augmenting the growth of the immunotherapy market include the increasing prevalence of auto-immune diseases among adults and the increasing investments in research and funding of cancer. For instance, in July 2021 The Cancer Research Institute (CRI), one of the US nonprofit organizations which are work in the discovery, and development of powerful immunotherapies for all cancers, was announced that it was awarded more than $28.5 million in research grants and fellowships during the 2021 fiscal year ending June 30, 2021

Moreover, the approval of immunotherapy for cancer treatment increasing monoclonal body production, which is also driving the market growth. For instance, in July 2021, the US FDA approved pembrolizumab (Keytruda), which is used in the treatment of patients diagnosed with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment. Technological development is also estimated to be the prime factor that is contributing significantly towards the growth of the market, such as the real-time, noninvasive visualization of specific cells, or the application of artificial intelligence (AI) to pathology, which have garnered recent attention in the immunotherapy market. However, the high treatment costs and low purchasing power of consumers are expected to hamper the growth of the global immunotherapy market.

The COVID-19 pandemic has had a negative impact on global Immunotherapy, the pandemic affected the buying capacity of hospitals, mainly small-scale hospitals and scanning centers. As per the recent article by Cigna, there have been reductions in hospitalizations for non-elective conditions such as transient ischemic attacks that raise the possibility that patients may be deferring necessary elements of clinical care, also the COVID-19 pandemic has affected the clinical trials of the new cancer immunotherapy drugs are kept on hold. However, the market was observed to be increased during the forecast period

The market is segmented based on type, applications, and end-user. By type, the market is segmented into monoclonal antibodies, cancer vaccines, autoimmune checkpoint inhibitors, cytokinin's, &others. Further, based on the application segment, the market is segmented into cancer, autoimmune and inflammatory diseases, infectious diseases, and others. Based on the end-user segment the market is segmented into hospitals, diagnostic centers, and others end-user.

Among these, the hospital segment is projected to grow at a substantial rate over the forecast period. This is due to the high access of hospitals for the treatment of chronic diseases. Most hospitals, especially in the cases related to cancer immunotherapy that center on indicative conditions. Also, the support of cancer vaccines, cellular therapies along experimental drugs enhances the immune system to fight cancer is leads to segmental growth. For instance, Northside Hospital Cancer Institute (NHCI) in the US has been offering immunotherapy for a longer period in the form of allogeneic stem cell transplantation.

Key players of the global immunotherapy market include AbbVie Inc, AstraZeneca, Bristol-Myers Squibb Company, Novartis AG, Merck &Co., Inc. These players are different growth strategies such as mergers &acquisitions, partnerships, new product launches, and geographical expansion among others to remain competitive in the market place.

The global immunotherapy market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is bifurcated into North America, Europe, Asia Pacific, and the Rest of the World. North America is estimated to be one of the leading regions in the global immunotherapy market. Some factors that are boosting the market growth in North America are the growing pervasiveness of cancer along with autoimmune diseases, increasing demand for safe and secure therapies related to cancer, rising acquiescence from the FDA. Asia Pacific is estimated to exhibit remarkable growth during the forecast period 2021-2027.

Research Methodology

The market study of the global Immunotherapy market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include

Financial reports of companies involved in the market

Whitepapers, research-papers, and news blogs

Company websites and their product catalog

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global Immunotherapy Market Research and Analysis by Type

Global Immunotherapy Market Research and Analysis by Application

Global Immunotherapy Market Research and Analysis by End-User

The Report Covers

Comprehensive research methodology of the global Immunotherapy market

This report also includes a detailed and extensive market overview with key analyst insights

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations

Analysis of regional regulations and other government policies impacting the global Immunotherapy market

Insights about market determinants which are stimulating the global immunotherapy market

Detailed and extensive market segments with regional distribution of forecast revenues

Extensive profiles and recent developments of the market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
      • 3.1.1.1. Overview
      • 3.1.1.2. Financial Analysis
      • 3.1.1.3. SWOT Analysis
      • 3.1.1.4. Recent Developments
  • 3.2 Key Strategy Analysis

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Immunotherapy Market by Type
    • 5.1.1. Monoclonal Antibodies
    • 5.1.2. Cancer Vaccines
    • 5.1.3. Autoimmune Checkpoint Inhibitors
    • 5.1.4. Interleukins and Interferons (Cytokinins)
    • 5.1.5. . Other
  • 5.2. Global Immunotherapy Market by Application
    • 5.2.1. Cancer
    • 5.2.2. Autoimmune and Inflammatory Diseases
    • 5.2.3. Infectious Diseases
    • 5.2.4. Other
  • 5.3. Global Immunotherapy Market by End-User
    • 5.3.1. Hospitals
    • 5.3.2. Diagnostic Centers
    • 5.3.3. Other

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Advaxis, Inc.
  • 7.2. AbbVie Inc.
  • 7.3. AstraZeneca PLC
  • 7.4. Adaptimmune Therapeutics plc.
  • 7.5. Agenus, Inc.
  • 7.6. Atara Biotherapeutics, Inc.
  • 7.7. BellicumPhamaceuticals, Inc.
  • 7.8. Bristol-Myers Squibb Company
  • 7.9. bluebird bio, Inc.
  • 7.10. Chinook Therapeutics, Inc.
  • 7.11. Celldex Therapeutics, Inc.
  • 7.12. CytomX Therapeutics, Inc.
  • 7.13. Gilead Sciences, Inc.
  • 7.14. Incyte Corp.
  • 7.15. Johnson & Johnson Services, Inc.
  • 7.16. Jounce Therapeutics, Inc.
  • 7.17. MacroGenics, Inc.
  • 7.18. Novartis AG
  • 7.19. Merck & Co., Inc.,
  • 7.20. Xencor, Inc.
  • 7.21. Ziopharm Oncology, Inc.

LIST OF TABLES

  • 1. GLOBAL IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 2. GLOBAL MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 3. GLOBAL CANCER VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL AUTOIMMUNE CHECKPOINT INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL INTERFERON AND INTERLEUKINS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 7. GLOBAL IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
  • 8. GLOBAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL AUTOIMMUNE AND INFLAMMATORY DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL INFECTIOUS DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBAL IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 13. GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 14. GLOBAL DIAGNOSTIC CENTRES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 15. GLOBAL OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 16. GLOBAL IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 17. NORTH AMERICAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 18. NORTH AMERICAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 19. NORTH AMERICAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
  • 20. NORTH AMERICAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 21. EUROPEAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 22. EUROPEAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 23. EUROPEAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
  • 24. EUROPEAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 25. ASIA-PACIFIC IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 26. ASIA-PACIFIC IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 27. ASIA-PACIFIC IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
  • 28. ASIA-PACIFIC IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 29. REST OF THE WORLD IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 30. REST OF THE WORLD IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
  • 31. REST OF THE WORLD IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL IMMUNOTHERAPY MARKET SHARE BY TYPE, 2020VS 2027 (%)
  • 2. GLOBAL IMMUNOTHERAPY MARKET SHARE BY APPLICATION, 2020VS 2027 (%)
  • 3. GLOBAL IMMUNOTHERAPY MARKET SHARE BY END-USER, 2020VS 2027 (%)
  • 4. GLOBAL IMMUNOTHERAPY MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 5. GLOBAL MONOCLONAL ANTIBODIES MARKET SHARE, BY GEOGRAPHY 2020-2027($ MILLION)
  • 6. GLOBAL AUTOIMMUNE CHECKPOINT INHIBITORS MARKET SHARE, BY GEOGRAPHY 2020-2027($ MILLION)
  • 7. GLOBAL INTERFERON AND INTERLEUKINS MARKET SHARE, BY GEOGRAPHY 2020-2027($ MILLION)
  • 8. GLOBAL OTHER MARKET SHARE, BY GEOGRAPHY 2020-2027($ MILLION)
  • 9. GLOBAL CANCER MARKET SHARE, BY GEOGRAPHY 2020-2027($ MILLION)
  • 10. GLOBAL AUTOIMMUNE AND INFLAMMATORY DISEASES MARKET SHARE, BY GEOGRAPHY 2020-2027($ MILLION)
  • 11. GLOBAL INFECTIOUS DISEASES MARKET SHARE, BY GEOGRAPHY 2020-2027($ MILLION)
  • 12. GLOBAL OTHER MARKET SHARE, BY GEOGRAPHY 2020-2027($ MILLION)
  • 13. GLOBAL HOSPITALS MARKET SHARE, BY GEOGRAPHY 2020-2027($ MILLION)
  • 14. GLOBAL DIAGNOSTIC CENTRES MARKET SHARE, BY GEOGRAPHY 2020-2027($ MILLION)
  • 15. GLOBAL OTHER MARKET SHARE, BY GEOGRAPHY 2020-2027($ MILLION)
  • 16. US IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
  • 17. CANADA IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
  • 18. UK IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
  • 19. FRANCE IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
  • 20. GERMANY IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
  • 21. ITALY IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
  • 22. SPAIN IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
  • 23. REST OF EUROPE IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
  • 24. ASIA-PACIFIC IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
  • 25. INDIA IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
  • 26. CHINA IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. JAPAN IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
  • 28. REST OF ASIA-PACIFIC IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)

29. REST OF THE WORLD IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION))